Trial of PACEBOM versus CHOP in histologically aggressive non-Hodgkins lymphoma

ISRCTN	ISRCTN24219839
DOI	https://doi.org/10.1186/ISRCTN24219839
Secondary identifying numbers	LY3

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study design	Randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details below to request a patient information sheet
Scientific title
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Lymphoma (non-Hodgkins)
Intervention	Patients were randomised to one of two regimens: 1. CHOP Regimen: Multi-drug chemotherapy with cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone (CHOP) repeated every 28 days. A minimum of six courses to be given with two courses beyond the attainment of complete response 2. PACEBOM Regimen: Multi-drug chemotherapy with prednisolone, adriamycin, cyclophosphamide and etoposide (PACE) alternating every 7 days with bleomycin, vincristine and methotrexate (BOM). Six cycles of PACE and five of BOM to be given
Intervention type	Other
Primary outcome measure	Not provided at time of registration
Secondary outcome measures	Not provided at time of registration
Overall study start date	01/11/1987
Completion date	31/10/1992

Participant type(s)	Patient
Age group	Not Specified
Sex
Target number of participants	Not provided at time of registration
Key inclusion criteria	1. Aged 16 to 69 years 2. Previously untreated histologically aggressive lymphoma with a large cell component: Diffuse large cell, Diffuse immunoblastic, Diffuse mixed cell 3. Stages II-IV 4. No contraindications to treatment protocols
Key exclusion criteria	Patients with Burkitt's and lymphoblastic lymphoma to be excluded
Date of first enrolment	01/11/1987
Date of final enrolment	31/10/1992

UKCCCR Register Co-ordinator

London
NW1 2DA
United Kingdom

Cancer Research UK (CRUK) (UK)
Charity

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom

Charity

Cancer Research UK
Private sector organisation / Other non-profit organizations

Alternative name(s): CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK
Location: United Kingdom

Lymphoma Research Trust

No information available

Lisa Lear Fund

No information available

Isle of Man Anti-Cancer Association

No information available

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/1996		Yes	No